Gilead Sciences annual return on assets (roa)
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gilead Sciences Return on Assets (ROA) Growth & History (GILD)
Gilead Sciences's return on assets (roa) was 14.42% for fiscal 2025.
View full Gilead Sciences company overviewGilead Sciences annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 14.42% | +13.63 pp |
| 2024 | 2024-12-31 | 0.79% | −8.25 pp |
| 2023 | 2023-12-31 | 9.04% | +2.04 pp |
| 2022 | 2022-12-31 | 7.00% | −2.13 pp |
| 2021 | 2021-12-31 | 9.13% | +8.94 pp |
| 2020 | 2020-12-31 | 0.19% | −8.41 pp |
| 2019 | 2019-12-31 | 8.60% | +0.45 pp |
| 2018 | 2018-12-31 | 8.14% | +0.87 pp |
| 2017 | 2017-12-31 | 7.27% | −17.57 pp |
| 2016 | 2016-12-31 | 24.84% | −17.08 pp |
| 2015 | 2015-12-31 | 41.93% | −0.35 pp |
| 2014 | 2014-12-31 | 42.28% | +28.24 pp |
| 2013 | 2013-12-31 | 14.04% | +0.59 pp |
| 2012 | 2012-12-31 | 13.45% | −5.96 pp |
| 2011 | 2011-12-31 | 19.41% | −7.85 pp |
| 2010 | 2010-12-31 | 27.25% | −4.44 pp |
| 2009 | 2009-12-31 | 31.69% | — |
Gilead Sciences quarterly return on assets (roa)
Q1.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −6.17% | −17.71 pp |
| Q1 2026 | 2026-03-31 | 16.35% | +5.77 pp |
| Q4 2025 | 2025-12-31 | 14.42% | +13.63 pp |
| Q3 2025 | 2025-09-30 | 14.35% | +14.13 pp |
| Q2 2025 | 2025-06-30 | 11.55% | +9.73 pp |
| Q1 2025 | 2025-03-31 | 10.58% | +9.76 pp |
| Q4 2024 | 2024-12-31 | 0.79% | −8.25 pp |
| Q3 2024 | 2024-09-30 | 0.22% | −9.19 pp |
| Q2 2024 | 2024-06-30 | 1.82% | −6.94 pp |
| Q1 2024 | 2024-03-31 | 0.82% | −8.12 pp |
| Q4 2023 | 2023-12-31 | 9.04% | +2.04 pp |
| Q3 2023 | 2023-09-30 | 9.41% | +4.26 pp |
| Q2 2023 | 2023-06-30 | 8.76% | +2.44 pp |
| Q1 2023 | 2023-03-31 | 8.94% | +2.02 pp |
| Q4 2022 | 2022-12-31 | 7.00% | −2.13 pp |
| Q3 2022 | 2022-09-30 | 5.14% | −6.41 pp |
| Q2 2022 | 2022-06-30 | 6.32% | −2.01 pp |
| Q1 2022 | 2022-03-31 | 6.92% | +6.44 pp |
| Q4 2021 | 2021-12-31 | 9.13% | +8.94 pp |
| Q3 2021 | 2021-09-30 | 11.56% | +9.44 pp |
| Q2 2021 | 2021-06-30 | 8.33% | +8.76 pp |
| Q1 2021 | 2021-03-31 | 0.47% | −7.62 pp |
| Q4 2020 | 2020-12-31 | 0.19% | −8.41 pp |
| Q3 2020 | 2020-09-30 | 2.11% | −2.25 pp |
| Q2 2020 | 2020-06-30 | −0.43% | −9.70 pp |
| Q1 2020 | 2020-03-31 | 8.10% | −1.09 pp |
| Q4 2019 | 2019-12-31 | 8.60% | +0.45 pp |
| Q3 2019 | 2019-09-30 | 4.36% | +1.90 pp |
| Q2 2019 | 2019-06-30 | 9.26% | +5.75 pp |
| Q1 2019 | 2019-03-31 | 9.19% | +3.56 pp |
| Q4 2018 | 2018-12-31 | 8.14% | +0.87 pp |
| Q3 2018 | 2018-09-30 | 2.46% | −16.67 pp |
| Q2 2018 | 2018-06-30 | 3.52% | −18.64 pp |
| Q1 2018 | 2018-03-31 | 5.63% | −18.34 pp |
| Q4 2017 | 2017-12-31 | 7.27% | −17.57 pp |
| Q3 2017 | 2017-09-30 | 19.13% | −8.98 pp |
| Q2 2017 | 2017-06-30 | 22.16% | −14.52 pp |
| Q1 2017 | 2017-03-31 | 23.96% | −16.32 pp |
| Q4 2016 | 2016-12-31 | 24.84% | −17.08 pp |
| Q3 2016 | 2016-09-30 | 28.11% | −14.44 pp |
| Q2 2016 | 2016-06-30 | 36.67% | −6.08 pp |
| Q1 2016 | 2016-03-31 | 40.29% | −2.51 pp |
| Q4 2015 | 2015-12-31 | 41.93% | −0.35 pp |
| Q3 2015 | 2015-09-30 | 42.56% | +5.90 pp |
| Q2 2015 | 2015-06-30 | 42.75% | +15.02 pp |
| Q1 2015 | 2015-03-31 | 42.79% | +24.58 pp |
| Q4 2014 | 2014-12-31 | 42.28% | +28.24 pp |
| Q3 2014 | 2014-09-30 | 36.66% | +22.63 pp |
| Q2 2014 | 2014-06-30 | 27.73% | +14.13 pp |
| Q1 2014 | 2014-03-31 | 18.21% | +4.59 pp |
| Q4 2013 | 2013-12-31 | 14.04% | +0.59 pp |
| Q3 2013 | 2013-09-30 | 14.03% | −0.82 pp |
| Q2 2013 | 2013-06-30 | 13.60% | −0.02 pp |
| Q1 2013 | 2013-03-31 | 13.62% | −0.32 pp |
| Q4 2012 | 2012-12-31 | 13.45% | −3.89 pp |
| Q3 2012 | 2012-09-30 | 14.84% | −5.65 pp |
| Q2 2012 | 2012-06-30 | 13.62% | −9.74 pp |
| Q1 2012 | 2012-03-31 | 13.94% | −9.84 pp |
| Q4 2011 | 2011-12-31 | 17.33% | −10.93 pp |
| Q3 2011 | 2011-09-30 | 20.49% | −10.49 pp |
| Q2 2011 | 2011-06-30 | 23.36% | — |
| Q1 2011 | 2011-03-31 | 23.78% | −9.13 pp |
| Q4 2010 | 2010-12-31 | 28.26% | — |
| Q3 2010 | 2010-09-30 | 30.98% | — |
| Q1 2010 | 2010-03-31 | 32.91% | — |
Gilead Sciences return on assets (roa) trends
Over the last five fiscal years, Gilead Sciences's return on assets (roa) increased from 0.19% to 14.42%, a change of +14.23 percentage points. The latest reported quarter, Q2 2026, shows −6.17%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gilead Sciences source filings ↗Community posts
Gilead raises its sales outlook but projects a deeper acquisition-driven annual loss
Gilead ($GILD) increased its 2026 product-sales forecast to $31.0–$31.3 billion from $30.1–$30.4 billion after third-quarter 2026 product revenue rose 13% to $8.3 billion. HIV sales grew 18% to $6.2 billion, supported by demand, pricing and ...
Gilead agrees $1.275 billion purchase of PepStar's oral inflammation program
Gilead ($GILD) agreed to acquire worldwide rights to PepStar's investigational oral IL-23 receptor inhibitor program, led by HCXT-2001. The agreement calls for $1.275 billion in upfront cash consideration payable at closing, subject to cust ...
